Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Anteris Reports Early DurAVR Heart Valve Study Results

AVR: $9.15 +3.62% · MC: $876M

Anteris Technologies Global Corp. reported no valve-related deaths or moderate or severe leaks one month after treatment in a small study of its medium-size DurAVR heart valve. The study also found no moderate or severe mismatch between the valve opening and patients’ blood-flow needs. A larger randomised trial comparing DurAVR with commercially available valves is enrolling patients.

Source announcements: 2026-11-02 09:40 to 2026-11-02 09:40 Sydney time
Story updated 2026-11-02 15:32 Sydney time
SourcesMedium-Size DurAVR THV Outcomes - Embark Study
Comments